Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW003 in Obese Participants With Obstructive Sleep Apnea
NCT07434050Phase 3Recruiting
- Sponsor
- Sciwind Biosciences
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of ecnoglutide in obstructive sleep apnea (OSA), obesity, sponsored by Sciwind Biosciences. Started Mar 2026; status: recruiting.
02
Drugs
ecnoglutide
03
Conditions
obstructive sleep apnea (OSA)obesity
Beyond the preview
Go deeper on NCT07434050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07434050.